BlueRock exercises option to license cell therapy candidate
The OpCT-001 iPSC cell therapy candidate is intended for treating primary photoreceptor diseases. The latest move marks the first iPSC therapy candidate to be licensed from the strategic
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Kyverna Therapeutics’ chimeric antigen receptor (CAR) T-cell product candidate, KYV-101 for treating refractory stiff-person syndrome (SPS).
This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia,